Literature DB >> 28229300

Significance of lymph node metastasis in pancreatic neuroendocrine tumor.

Katsunobu Taki1, Daisuke Hashimoto1, Shigeki Nakagawa1, Nobuyuki Ozaki2, Shinjiro Tomiyasu3, Masaki Ohmuraya4, Kota Arima1, Takayoshi Kaida1, Takaaki Higashi1, Keita Sakamoto1, Kazuya Sakata1, Hirohisa Okabe1, Hidetoshi Nitta1, Hiromitsu Hayashi1, Akira Chikamoto1, Toru Beppu1, Hiroshi Takamori2, Masahiko Hirota3, Hideo Baba5.   

Abstract

PURPOSE: Pancreatic neuroendocrine tumor (PNET) is relatively rare and has a generally better prognosis than does pancreatic cancer. However, as its prognosis in patients with lymph node metastasis (LNM) is unclear, lymph node dissection for PNET is controversial. Our study aimed to clarify the significance of LNM in PNET.
METHODS: We retrospectively examined 83 PNET patients who underwent pancreatic resections with lymph node dissection at Kumamoto University Hospital, Saiseikai Kumamoto Hospital, and Kumamoto Regional Medical Center from April 2001 to December 2014. Their clinicopathological parameters were analyzed by the absence or presence of LNM, and with regard to the disease-free survival (DFS) and overall survival (OS). A predictive score of LNM was also made using the age, tumor size, primary tumor location, and tumor function.
RESULTS: Although the 5-year OS was 74.8% for LNM+ and 94.6% for LNM- (P = 0.002), LNM was not an independent risk factor for the OS in a multivariate analysis. However, tumors larger than 1.8 cm were found to be an independent prognostic factor, and the cut-off value for the predictive score was 1.69.
CONCLUSIONS: Although LNM was not an independent prognostic factor, lymph node dissection is recommended for patients whose predictive score is larger than 1.69.

Entities:  

Keywords:  Lymph node metastasis; Neuroendocrine tumor; Pancreas; Pancreatic neuroendocrine tumor; Prognosis

Mesh:

Year:  2017        PMID: 28229300     DOI: 10.1007/s00595-017-1485-y

Source DB:  PubMed          Journal:  Surg Today        ISSN: 0941-1291            Impact factor:   2.549


  28 in total

1.  Surgical strategies for non-functioning pancreatic neuroendocrine tumours.

Authors:  M J Kim; D W Choi; S H Choi; J S Heo; H J Park; K K Choi; K-T Jang; J-Y Sung
Journal:  Br J Surg       Date:  2012-11       Impact factor: 6.939

2.  Prognostic factors in pancreatic endocrine neoplasms: an analysis of 136 cases with a proposal for low-grade and intermediate-grade groups.

Authors:  Steven N Hochwald; Sui Zee; Kevin C Conlon; Roberto Colleoni; Otway Louie; Murray F Brennan; David S Klimstra
Journal:  J Clin Oncol       Date:  2002-06-01       Impact factor: 44.544

3.  Regional lymphadenectomy is indicated in the surgical treatment of pancreatic neuroendocrine tumors (PNETs).

Authors:  Yassar M Hashim; Kathryn M Trinkaus; David C Linehan; Steven S Strasberg; Ryan C Fields; Dengfeng Cao; William G Hawkins
Journal:  Ann Surg       Date:  2014-02       Impact factor: 12.969

4.  Outcome of surgery for pancreatic neuroendocrine neoplasms.

Authors:  L Fischer; F Bergmann; S Schimmack; U Hinz; S Prieß; B P Müller-Stich; J Werner; T Hackert; M W Büchler
Journal:  Br J Surg       Date:  2014-08-13       Impact factor: 6.939

Review 5.  One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States.

Authors:  James C Yao; Manal Hassan; Alexandria Phan; Cecile Dagohoy; Colleen Leary; Jeannette E Mares; Eddie K Abdalla; Jason B Fleming; Jean-Nicolas Vauthey; Asif Rashid; Douglas B Evans
Journal:  J Clin Oncol       Date:  2008-06-20       Impact factor: 44.544

6.  Basing treatment strategy for non-functional pancreatic neuroendocrine tumors on tumor size.

Authors:  Yoji Kishi; Kazuaki Shimada; Satoshi Nara; Minoru Esaki; Nobuyoshi Hiraoka; Tomoo Kosuge
Journal:  Ann Surg Oncol       Date:  2014-04-18       Impact factor: 5.344

7.  Prognostic score predicting survival after resection of pancreatic neuroendocrine tumors: analysis of 3851 patients.

Authors:  Karl Y Bilimoria; Mark S Talamonti; James S Tomlinson; Andrew K Stewart; David P Winchester; Clifford Y Ko; David J Bentrem
Journal:  Ann Surg       Date:  2008-03       Impact factor: 12.969

8.  Nonfunctioning neuroendocrine pancreatic tumors: our experience and management.

Authors:  Naohiro Nomura; Tsutomu Fujii; Naohito Kanazumi; Shin Takeda; Shuji Nomoto; Hideki Kasuya; Hiroyuki Sugimoto; Suguru Yamada; Akimasa Nakao
Journal:  J Hepatobiliary Pancreat Surg       Date:  2009-04-14

9.  Clinical outcome and long-term survival in 118 consecutive patients with neuroendocrine tumours of the pancreas.

Authors:  L Fischer; J Kleeff; I Esposito; U Hinz; A Zimmermann; H Friess; M W Büchler
Journal:  Br J Surg       Date:  2008-05       Impact factor: 6.939

10.  Clinicopathological characteristics and prognosis-related factors of resectable pancreatic neuroendocrine tumors: a retrospective study of 104 cases in a single Chinese center.

Authors:  Xu Han; Xuefeng Xu; Dayong Jin; Dansong Wang; Yuan Ji; Wenhui Lou
Journal:  Pancreas       Date:  2014-05       Impact factor: 3.327

View more
  9 in total

1.  Role of Lymph Node Resection and Histopathological Evaluation in Accurate Staging of Nonfunctional Pancreatic Neuroendocrine Tumors: How Many Are Enough?

Authors:  Ding Ding; Ammar A Javed; Chunhui Yuan; Michael J Wright; Zunaira N Javed; Jonathan A Teinor; I Chae Ye; Richard A Burkhart; John L Cameron; Matthew J Weiss; Christopher L Wolfgang; Jin He
Journal:  J Gastrointest Surg       Date:  2020-02-05       Impact factor: 3.452

Review 2.  Systematic Review and Metaanalysis of Lymph Node Metastases of Resected Pancreatic Neuroendocrine Tumors.

Authors:  Masayuki Tanaka; Max Heckler; André L Mihaljevic; Pascal Probst; Ulla Klaiber; Ulrike Heger; Simon Schimmack; Markus W Büchler; Thilo Hackert
Journal:  Ann Surg Oncol       Date:  2020-07-27       Impact factor: 5.344

Review 3.  Prognostic and predictive factors on overall survival and surgical outcomes in pancreatic neuroendocrine tumors: recent advances and controversies.

Authors:  Lingaku Lee; Tetsuhide Ito; Robert T Jensen
Journal:  Expert Rev Anticancer Ther       Date:  2019-11-27       Impact factor: 4.512

4.  Risk factors for lymph node metastasis in patients with pancreatic neuroendocrine neoplasms.

Authors:  Yosuke Nakao; Hiromitsu Hayashi; Yo-Ichi Yamashita; Ofuchi Takashi; Kazuki Matsumura; Norio Uemura; Fumimasa Kitamura; Rumi Itoyama; Toshihiko Yusa; Katsunobu Taki; Tatsunori Miyata; Takaaki Higashi; Shigeki Nakagawa; Hirohisa Okabe; Katsunori Imai; Hideo Baba
Journal:  World J Clin Oncol       Date:  2022-06-24

5.  A case of successful conversion from everolimus to surgical resection of a giant pancreatic neuroendocrine tumor.

Authors:  Asahi Sato; Toshihiko Masui; Nao Sankoda; Kenzo Nakano; Yuichiro Uchida; Takayuki Anazawa; Kyoichi Takaori; Yoshiya Kawaguchi; Shinji Uemoto
Journal:  Surg Case Rep       Date:  2017-07-20

6.  A meta-analysis of Prognostic factor of Pancreatic neuroendocrine neoplasms.

Authors:  Yong Gao; Hao Gao; Guangfu Wang; Lingdi Yin; Wenbin Xu; Yunpeng Peng; Junli Wu; Kuirong Jiang; Yi Miao
Journal:  Sci Rep       Date:  2018-05-08       Impact factor: 4.379

7.  The latest exploration of staging and prognostic classification for pancreatic neuroendocrine tumors: a large population-based study.

Authors:  Shanshan Gao; Ning Pu; Lingxiao Liu; Changyu Li; Xuefeng Xu; Xiaolin Wang; Wenhui Lou
Journal:  J Cancer       Date:  2018-04-19       Impact factor: 4.207

8.  Predicting Selection Preference of Robotic Pancreaticoduodenectomy (RPD) in a Chinese Single Center Population: Development and Assessment of a New Predictive Nomogram.

Authors:  Zhen Huo; Zhihao Shi; Shuyu Zhai; Jingfeng Li; Hao Qian; Xiaomei Tang; Yuanchi Weng; Yusheng Shi; Liwen Wang; Yue Wang; Xiaxing Deng; Baiyong Shen
Journal:  Med Sci Monit       Date:  2019-10-26

9.  c-Myc promotes lymphatic metastasis of pancreatic neuroendocrine tumor through VEGFC upregulation.

Authors:  Tsung-Ming Chang; Pei-Yi Chu; Wen-Chun Hung; Yan-Shen Shan; Hui-You Lin; Kuo-Wei Huang; Jeffrey S Chang; Li-Tzong Chen; Hui-Jen Tsai
Journal:  Cancer Sci       Date:  2020-11-24       Impact factor: 6.518

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.